Patents Assigned to Beijing Hanmi Pharm. Co., Ltd.
  • Patent number: 11591409
    Abstract: Provided are an anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and a preparation thereof. In particular, provided are a highly stable heterodimeric anti-PD-L1/anti-PD-1 bispecific antibody with characteristics of a natural IgG and without mismatches heavy chain-light chain, and a preparation thereof. The bispecific antibody can bind to both target molecules and is more effective in treating a complex disease.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 28, 2023
    Assignee: BEIJING HANMI PHARM. CO., LTD.
    Inventors: Jiawang Liu, Nanmeng Song, Yaping Yang, Mengxie Jin
  • Patent number: 11117967
    Abstract: An antibody specifically binding to PD-1 and a functional fragment thereof. The antibody or functional fragment thereof includes a PD-1 chimeric antibody and a functional fragment thereof, and a PD-1 humanized antibody and a functional fragment thereof.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: September 14, 2021
    Assignee: BEIJING HANMI PHARM. CO., LTD.
    Inventors: Yaping Yang, Jiawang Liu, Nanmeng Song, Hongjuan Zhang, Mengxie Jin
  • Patent number: 11072651
    Abstract: An antibody specifically binding to IL-17A or a functional fragment thereof. The antibody or functional fragment thereof includes an IL-17A chimeric antibody and a functional fragment thereof, and an IL-17A humanized antibody and a functional fragment thereof.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: July 27, 2021
    Assignee: BEIJING HANMI PHARM. CO., LTD.
    Inventors: Nanmeng Song, Jiawang Liu, Yaping Yang, Yang Yang, Dongge Yang, Hongjuan Zhang, Mengxie Jin
  • Publication number: 20200299412
    Abstract: Provided are an anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and a preparation thereof. In particular, provided are a highly stable heterodimeric anti-PD-L1/anti-PD-1 bispecific antibody with characteristics of a natural IgG and without mismatches heavy chain-light chain, and a preparation thereof. The bispecific antibody can bind to both target molecules and is more effective in treating a complex disease.
    Type: Application
    Filed: March 28, 2018
    Publication date: September 24, 2020
    Applicant: BEIJING HANMI PHARM. CO., LTD.
    Inventors: Jiawang Liu, Nanmeng Song, Yaping Yang, Mengxie Jin
  • Publication number: 20200172529
    Abstract: Provided are a pyrimidinyl amino compound having protein kinase inhibitor activity, and a pharmaceutical composition containing said compound; also provided are a use and application of said compound. What is provided is selected from a group consisting of the compound represented by formula (I), a stereoisomer thereof, a tautomer thereof, a pharmacologically acceptable salt thereof, a solvate thereof, and a prodrug thereof. The described compound has good inhibitory activity against the JAK family of kinases and the SYK family of kinases, and therefore may serve as a JAK inhibitor and SYK inhibitor, and is effective in use for the prevention or treatment of diseases related to the JAK and SYK families of kinases.
    Type: Application
    Filed: August 17, 2018
    Publication date: June 4, 2020
    Applicant: Beijing Hanmi Pharm. Co., Ltd.
    Inventors: Tao ZHAO, Dong WEI, Min LI, Maeng Sup KIM, Chul Woong CHUNG